earnings
confidence high
sentiment neutral
materiality 0.70
LENSAR Q2 revenue $8.0M (+1% YoY), net loss ($6.8M); FDA OK for ALLY system
LENSAR, Inc.
2022-Q2 EPS reported
-$1.34
revenue$17,378,000
- Net loss of ($6.8M) or ($0.67)/share vs. ($4.4M) or ($0.47)/share in Q2 2021.
- Total procedure volume up 8% to 33,359; U.S. volume up 15% vs. Q2 2021.
- Selling, general & administrative expenses rose 37% to $7.6M; R&D up 28% to $3.8M.
- Adjusted EBITDA (ex stock comp) was ($4.3M) vs. ($2.3M) a year ago.
- FDA cleared ALLY Adaptive Cataract Treatment System in June; expects ~10 U.S. placements in 2022.